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neuropathy, the published article states, “Plasma 
exchange, cyclophosphamide, and intravenous im-
mune globulin are all beneficial. . . .” However, 
in my original discussion of this case, I mentioned 
treatment with plasma exchange only in reference 
to early reports describing treatment of multifo-
cal motor neuropathy with plasma exchange and 
cyclophosphamide in combination. My original 
statement was as follows: “Initial treatment stud-
ies described beneficial effects of plasma exchange 
and cyclophosphamide. Prednisone, in contrast, 
is ineffective and may worsen the disease. Subse-
quent studies have demonstrated the beneficial 
effects of intravenous immunoglobulin in multi-
focal motor neuropathy and the favorable risk-to-
benefit ratio of this therapy relative to that of 
cytotoxic therapy has made IVIg the initial treat-
ment of choice in these patients.” This statement 
was changed during the editorial process, and 
the change erroneously implied that treatment of 
multifocal motor neuropathy with plasma exchange 
is beneficial.
William J. Triggs, M.D.
McKnight Brain Institute 
Gainesville, FL 32611
Two Doses of Azithromycin to Eliminate Trachoma  
in a Tanzanian Community
To the Editor: Single-dose azithromycin is the 
first-choice antibiotic for the treatment of tra-
choma. The World Health Organization (WHO) 
currently recommends annual mass azithromy-
cin treatment for 3 years in communities in which 
the prevalence of the clinical sign “trachomatous 
inflammation–follicular” in children between 
1 and 9 years of age is 10% or more.
We previously reported the effect of high-cov-
erage, single-dose mass azithromycin treatment on 
ocular Chlamydia trachomatis infection in Kahe Mpya, 
Tanzania.1 In all, 97.6% of residents were treated; 
the prevalence of ocular C. trachomatis fell from 
9.5% at baseline to 0.1% 24 months later. We sub-
sequently carried out a second round of mass 
treatment at 24 months, examined residents at 42 
and 60 months, and took conjunctival swabs for 
testing for C. trachomatis by means of a polymer-
ase-chain-reaction assay at 60 months. Just as at 
6, 12, and 18 months, at 42 months, persons with 
active disease (21 of the 821 residents examined at 
42 months) were offered tetracycline eye oint-
ment. Field, laboratory, and statistical methods 
have been described previously,1,2 although be-
cause we expected the prevalence of infection to 
be low after the two mass treatments, we com-
bined aliquots from each of five eluted swabs for 
each assay, intending to retest individual samples 
if results were positive or equivocal.3 Approval 
for the study was obtained from ethics commit-
tees at the London School of Hygiene and Tropi-
cal Medicine and Tumaini University.
At 24 months (when the prevalence of infec-
tion was 0.1%1), the rate of antibiotic coverage 
was 93.1% (917 of 985 persons). At 42 months, 
821 of 975 residents (84.2%) were examined, as 
were 859 of 964 (89.1%) at 60 months. The preva-
lence of trachomatous inflammation–follicular in 
children between 1 and 9 years of age fell from 
16.3% at 24 months to 4.6% at 42 months and 
2.6% at 60 months. At 60 months (3 years after 
the second mass treatment), C. trachomatis DNA 
was not detected in the conjunctiva of any of the 
859 residents from whom swab specimens were 
obtained, suggesting that infection may have been 
eliminated.
One or two rounds of high-coverage mass 
treatment with azithromycin may be sufficient 
to eliminate ocular C. trachomatis in communities 
with moderate levels of infection. In this Tanza-
nian community, the fall in the prevalence of 
trachomatous inflammation–follicular lagged con-
siderably behind the fall in the prevalence of in-
fection (Fig. 1). Had WHO recommendations on 
antibiotic use been followed, three or possibly five 
annual rounds of mass treatment would have 
been offered, whereas our data suggest that one 
round was sufficient. A field-based assay for esti-
mating the prevalence of infection4 is needed to 
guide treatment decisions in the 3 to 5 years after 
the first distribution of antibiotics for trachoma 
control.
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Figure 1. Prevalences of Ocular Chlamydia trachomatis Infection (Positive Result on Polymerase-Chain-Reaction  
Assay [PCR]) and Disease (Trachomatous Inflammation–Follicular) during Follow-up in a Tanzanian Community. 
The prevalence data for the first 24 months are from our previous report.1 The arrows indicate the timing of mass 
azithromycin treatment.
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